Literature DB >> 19808650

Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice.

Claudia Mitchell1, Marie-Anne Robin, Alicia Mayeuf, Meriem Mahrouf-Yorgov, Abdellah Mansouri, Marie Hamard, Dominique Couton, Bernard Fromenty, Hélène Gilgenkrantz.   

Abstract

Accumulating evidence indicates that oxidative stress is involved in the physiopathology of liver fibrogenesis. However, amid the global context of hepatic oxidative stress, the specific role of hepatocyte mitochondrial dysfunction in the fibrogenic process is still unknown. The aim of this study was to determine whether a targeted protection of hepatocytes against mitochondrial dysfunction could modulate fibrosis progression. We induced liver fibrogenesis by chronic carbon tetrachloride treatment (3 or 6 weeks of biweekly injections) in transgenic mice expressing Bcl-2 in their hepatocytes or in normal control mice. Analyses of mitochondrial DNA, respiratory chain complexes, and lipid peroxidation showed that Bcl-2 transgenic animals were protected against mitochondrial dysfunction and oxidative stress resulting from carbon tetrachloride injury. Picrosirius red staining, alpha-smooth muscle actin immunohistochemistry, and real-time PCR for transforming growth factor-beta and collagen alpha-I revealed that Bcl-2 transgenic mice presented reduced fibrosis at early stages of fibrogenesis. However, at later stages increased nonmitochondrial/nonhepatocytic oxidative stress eventually overcame the capacity of Bcl-2 overexpression to prevent the fibrotic process. In conclusion, we demonstrate for the first time that specific protection against hepatocyte mitochondrial dysfunction plays a preventive role in early stages of fibrogenesis, delaying its onset. However, with the persistence of the aggression, this protection is no longer sufficient to impede fibrosis progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808650      PMCID: PMC2774057          DOI: 10.2353/ajpath.2009.090332

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

Review 1.  Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

Authors:  Karima Begriche; Anissa Igoudjil; Dominique Pessayre; Bernard Fromenty
Journal:  Mitochondrion       Date:  2006-01-05       Impact factor: 4.160

2.  Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.

Authors:  Vincent Tong; Xiao Wei Teng; Thomas K H Chang; Frank S Abbott
Journal:  Toxicol Sci       Date:  2005-04-27       Impact factor: 4.849

3.  Alcohol increases tumor necrosis factor alpha and decreases nuclear factor-kappab to activate hepatic apoptosis in genetically obese mice.

Authors:  Marie-Anne Robin; Christine Demeilliers; Angéla Sutton; Valérie Paradis; Caroline Maisonneuve; Sylvie Dubois; Odile Poirel; Philippe Lettéron; Dominique Pessayre; Bernard Fromenty
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

Review 4.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

5.  Time-course of lipid peroxidation in different organs of mice treated with Echis pyramidum snake venom.

Authors:  Abdurrahman Al Asmari; Khalaf Al Moutaery; Rajamohamed Abbas Manthari; Haseeb Ahmad Khan
Journal:  J Biochem Mol Toxicol       Date:  2006       Impact factor: 3.642

6.  Deficiency of nicotinamide adenine dinucleotide phosphate, reduced form oxidase enhances hepatocellular injury but attenuates fibrosis after chronic carbon tetrachloride administration.

Authors:  Ghazaleh Aram; James J Potter; Xiaopu Liu; Lan Wang; Michael S Torbenson; Esteban Mezey
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

7.  Dietary trans-resveratrol bioavailability and effect on CCl4-induced liver lipid peroxidation.

Authors:  Paola Vitaglione; Barbara Ottanelli; Stefano Milani; Filomena Morisco; Nicola Caporaso; Vincenzo Fogliano
Journal:  J Gastroenterol Hepatol       Date:  2008-09-24       Impact factor: 4.029

8.  Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration.

Authors:  Ghazaleh Aram; James J Potter; Xiaopu Liu; Michael S Torbenson; Esteban Mezey
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

9.  Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis.

Authors:  Raquel Pérez; María García-Fernández; Matías Díaz-Sánchez; Juan E Puche; Gloria Delgado; Marian Conchillo; Jordi Muntané; Inma Castilla-Cortázar
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

10.  Glutathione binding to the Bcl-2 homology-3 domain groove: a molecular basis for Bcl-2 antioxidant function at mitochondria.

Authors:  Angela K Zimmermann; F Alexandra Loucks; Emily K Schroeder; Ron J Bouchard; Kenneth L Tyler; Daniel A Linseman
Journal:  J Biol Chem       Date:  2007-08-09       Impact factor: 5.157

View more
  24 in total

1.  Circulating mitochondrial DNA content associated with the risk of liver cirrhosis: a nested case-control study.

Authors:  Chun Wang; Hie-Won Hann; Richard S Hann; Shaogui Wan; Ronald E Myers; Zhong Ye; Jinliang Xing; Hushan Yang
Journal:  Dig Dis Sci       Date:  2015-01-15       Impact factor: 3.199

Review 2.  Mitochondrial stress: a bridge between mitochondrial dysfunction and metabolic diseases?

Authors:  Fang Hu; Feng Liu
Journal:  Cell Signal       Date:  2011-05-15       Impact factor: 4.315

3.  GLUT10 is required for the development of the cardiovascular system and the notochord and connects mitochondrial function to TGFβ signaling.

Authors:  Andy Willaert; Sandeep Khatri; Bert L Callewaert; Paul J Coucke; Seth D Crosby; Joseph G H Lee; Elaine C Davis; Sruti Shiva; Michael Tsang; Anne De Paepe; Zsolt Urban
Journal:  Hum Mol Genet       Date:  2011-11-24       Impact factor: 6.150

4.  Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet.

Authors:  Viviane Trak-Smayra; Valérie Paradis; Julie Massart; Selim Nasser; Victor Jebara; Bernard Fromenty
Journal:  Int J Exp Pathol       Date:  2011-11-25       Impact factor: 1.925

Review 5.  Targeting NOX enzymes in pulmonary fibrosis.

Authors:  Louise Hecker; Jeff Cheng; Victor J Thannickal
Journal:  Cell Mol Life Sci       Date:  2012-05-23       Impact factor: 9.261

Review 6.  Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis.

Authors:  David W Waters; Kaj E C Blokland; Prabuddha S Pathinayake; Janette K Burgess; Steven E Mutsaers; Cecilia M Prele; Michael Schuliga; Christopher L Grainge; Darryl A Knight
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-04-26       Impact factor: 5.464

7.  Toxicological Implications of Mitochondrial Localization of CYP2E1.

Authors:  Jessica H Hartman; Grover P Miller; Joel N Meyer
Journal:  Toxicol Res (Camb)       Date:  2017-03-14       Impact factor: 3.524

8.  Mitochondrial roles and cytoprotection in chronic liver injury.

Authors:  Davide Degli Esposti; Jocelyne Hamelin; Nelly Bosselut; Raphaël Saffroy; Mylène Sebagh; Alban Pommier; Cécile Martel; Antoinette Lemoine
Journal:  Biochem Res Int       Date:  2012-06-15

9.  Turnover rates of hepatic collagen and circulating collagen-associated proteins in humans with chronic liver disease.

Authors:  Martin L Decaris; Claire L Emson; Kelvin Li; Michelle Gatmaitan; Flora Luo; Jerome Cattin; Corelle Nakamura; William E Holmes; Thomas E Angel; Marion G Peters; Scott M Turner; Marc K Hellerstein
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

10.  NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development.

Authors:  Patricia Sancho; Jèssica Mainez; Eva Crosas-Molist; César Roncero; Conrado M Fernández-Rodriguez; Fernando Pinedo; Heidemarie Huber; Robert Eferl; Wolfgang Mikulits; Isabel Fabregat
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.